Unique hematopoietic growth stimulatory factors have been identified in the conditioned medium of a human bladder carcinoma cell line 5637. One of these, termed Pluripoietin, has been purified to homogeneity and is a protein of Mr18,000 that stimulates human and murine CFU-GM (day 7), BFU-E cfu-Mk., and CFU-GEMM. In addition it induces differentiation of the leukemic cell lines HL-60 and WEH1-3.A related pluripotent activity with alpha CSF-like properties is also identified and is distinguished from the former by ion-exchange chromatography and RP-HPLC. Its action is species restricted. This molecule also will be purifed to homogeneity and both pluripoietins (pCSF's) will be sequenced, cloned and used to raise monoclonal antibodies. Radioiodinated pCSF will be used for RIA development and radioreceptor analysis on normal and leukemic cells. In vitro action of the pCSF's will be investigated under serum-free conditions and in the absence of accessory cells that will be removed by a variety of procedures including monoclonal antibody panning, FACS and micromanipulation of single cells. Synergism between the two pCSF's will be investigated as will the requirement of a second factor such as erythropoietin, thrombopoietin, GM-CSF, CSF-1, G-CSF and Eo.-CSF, for full terminal differentiation of pluripotent stem cell targets. Purification of pluripotent stem cells will be undertaken using monoclonal antibodies in normal or long term human marrow cell suspensions and in murine 5-FU treated marrow and fetal yolk sac and liver. Very early stem cells (pre-CFU-GEMM, HPP-CFC) will be obtained by taking advantage of their lack of certain cell surface antigens defined by monoclonal abs.(anti-la, L4F3), their preferential localization in the adherent marrow, their dormant state and 5-FU resistance. Selective response of these cells to pCSF, Interleukin-3,CSF-2 and other CSF species will be studied and attempts made to develop continuous lines of normal or leukemic pluripotent stem cells. The cell type in the marrow (macrophage, T-cell, preadipocyte, endothelial cell) will be studied for factor production and biological role.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA032516-06
Application #
3170419
Study Section
(SSS)
Project Start
1982-09-15
Project End
1989-03-31
Budget Start
1987-12-01
Budget End
1989-03-31
Support Year
6
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Muench, M O; Firpo, M T; Moore, M A (1993) Bone marrow transplantation with interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. Blood 81:3463-73
Muench, M O; Gasparetto, C; Moore, M A (1992) The in vitro growth of murine high proliferative potential-colony forming cells is not enhanced by growth in a low oxygen atmosphere. Cytokine 4:488-94
Muench, M O; Guy, Z; Moore, M A (1992) Ex vivo differentiation therapy as a method of leukemic cell purging in murine bone marrow expansion cultures. Cancer Res 52:6576-82
Muench, M O; Schneider, J G; Moore, M A (1992) Interactions among colony-stimulating factors, IL-1 beta, IL-6, and kit-ligand in the regulation of primitive murine hematopoietic cells. Exp Hematol 20:339-49
Muench, M O; Moore, M A (1992) Accelerated recovery of peripheral blood cell counts in mice transplanted with in vitro cytokine-expanded hematopoietic progenitors. Exp Hematol 20:611-8
Steffen, M; Budde-Steffen, C; Gabrilove, J L et al. (1992) Modulation of leukemic cell growth by tumor necrosis factor: action and expression in myeloid leukemia. Leukemia 6:634-41
Moore, M A (1991) The future of cytokine combination therapy. Cancer 67:2718-26
Moore, M A (1991) Review: Stratton Lecture 1990. Clinical implications of positive and negative hematopoietic stem cell regulators. Blood 78:1-19
Warren, D J; Slordal, L; Moore, M A (1990) Tumor-necrosis factor induces cell cycle arrest in multipotential hematopoietic stem cells: a possible radioprotective mechanism. Eur J Haematol 45:158-63
Moore, M A (1990) Hematopoietic growth factors in cancer. Cancer 65:836-44

Showing the most recent 10 out of 26 publications